Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 1 of 1 for:    NAM-NK cells
Previous Study | Return to List | Next Study

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03019666
Recruitment Status : Recruiting
First Posted : January 12, 2017
Last Update Posted : June 12, 2019
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

Tracking Information
First Submitted Date  ICMJE January 11, 2017
First Posted Date  ICMJE January 12, 2017
Last Update Posted Date June 12, 2019
Actual Study Start Date  ICMJE October 18, 2017
Estimated Primary Completion Date April 30, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 11, 2017)
  • Occurrence of any grade 4 or greater suspected adverse reaction [ Time Frame: 24 hours post infusion ]
  • Occurrence of Grade III or IV acute graft-versus-host disease (aGVHD) [ Time Frame: 28 days post infusion ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03019666 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 11, 2017)
  • Occurrence of treatment related mortality (TRM) [ Time Frame: 2 months post infusion ]
  • Occurrence of disease response [ Time Frame: 28 days post infusion ]
  • Number of patients alive without progression [ Time Frame: 1 year post infusion ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
Official Title  ICMJE A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
Brief Summary This is a phase I trial with pilot expansion of HLA-haploidentical or HLA-mismatched related donor nicotinamide expanded-natural killer (NAM-NK) cell based therapy for patients with relapsed or refractory multiple myeloma (MM) or relapsed/refractory CD20-positive non-Hodgkin lymphoma (NHL). The primary endpoint of the study is to determine the maximum tolerated dose (MTD) of NAM-NK cells while maintaining safety.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Multiple Myeloma
  • Non-Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Mantle-Cell Lymphoma
  • Follicular Lymphoma
  • Indolent B Cell Lymphoma
  • Primary Mediastinal Lymphoma
  • Lymphoplasmacytic Lymphoma
Intervention  ICMJE Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Cyclophosphamide 40 mg/kg x 1 day on Day -5
  • Fludarabine 25 mg/m^2 x 3 days (Day -5, Day -4, day-3)
Other Name: NAM-NK
Study Arms  ICMJE
  • Experimental: Multiple Myeloma
    After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
    Intervention: Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Experimental: Non-Hodgkin Lymphoma
    After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
    Intervention: Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 11, 2017)
24
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 31, 2021
Estimated Primary Completion Date April 30, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Patient Inclusion Criteria:

  • ≥18 to ≤70 years of age
  • Meets one of the following disease criteria:

    • Multiple Myeloma (MM) meeting one of the following:

      • relapsed/refractory disease after two lines of therapies, including a proteasome inhibitor (bortezomib, carfilzomib or ixazomib) and an immunomodulatory drug (thalidomide, lenalidomide or pomalidomide)
      • relapsed disease between 2-18 months of 1st autologous stem cell transplantation,
      • relapsed disease at least 4 months after allogeneic stem cell transplantation with no evidence of active graft versus host disease and no availability of donor lymphocyte infusion
      • measurable disease defined as serum IgG, A, M M-protein ≥ 0.5g/dL or serum IgD M-protein ≥ 0.5 g/dL, or urine M-protein ≥ 200 mg/24 hours
      • at least 4 weeks since plasmapheresis
      • at least 3 days between last corticosteroids and study treatment start
    • CD20-positive B-cell Non-Hodgkin Lymphoma (NHL)

      • CD20 expression confirmed by flow cytometry or immunohistochemistry and meeting one or more of the following:

        • evidence of relapsed/refractory disease that has failed conventional therapy and failed/not eligible/refused studies of a higher priority,
        • relapsed disease at least 60 days after autologous stem cell transplantation
        • relapsed disease at least 4 months after allogeneic stem cell transplantation with no evidence of active graft versus host disease and no availability of donor lymphocyte infusion
        • has measurable disease >1.5 cm in diameter
  • HLA-haploidentical or mismatched related donor (aged 12 to 70 years) with donor/recipient match based on a minimum of intermediate resolution DNA based Class I typing of the A and B locus (at least 2/4 class I allele) and absence of recipient anti HLA antibodies against selected donor
  • Karnofsky Performance Status ≥ 60% - appendix III
  • Adequate organ function within 14 days of study registration (30 days for pulmonary and cardiac assessments) defined as:

    • Bone Marrow: Total white blood cell (WBC) count ≥ 3000/μL, absolute neutrophil count (ANC) ≥ 1000/μL, platelet count ≥ 75,000/μL and hemoglobin ≥ 8.0 g/dL - may be waived if abnormalities are due to disease related bone marrow involvement
    • Renal: creatinine ≤ 1.5 mg/dL or creatinine clearance ≥40mL/min using Cockcroft-Gault formula
    • Hepatic: ALT or AST ≤ 3 x upper limit of institutional normal (ULN), total bilirubin ≤ 1.5 x ULN
    • Pulmonary Function: oxygen saturation ≥ 90% on room air. If symptomatic or prior known impairment, pulmonary function ≥ 50% corrected DLCO and FEV1 is required
    • Cardiac Function: LVEF ≥ 40%, no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
    • Calcium (MM only): Corrected calcium < 11.5 mg/dL within 2 weeks prior to enrollment
  • Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to NAM-NK cell infusion (excluding preparative regimen pre-medications)
  • Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy
  • Must have recovered from acute effects of prior therapy - at least 2 weeks should have elapsed since the last dose of chemotherapy
  • Voluntary written consent

Patient Exclusion Criteria:

  • Active, untreated CNS involvement
  • Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), or high-grade lymphomas (Burkittt's lymphoma/Lymphoblastic lymphoma)
  • Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. For elotuzumab arm: Women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 14 days of study treatment start (24 hours prior to the start of elotuzumab)
  • Marked baseline prolongation of QT/QTc interval (e.g. demonstration of a QTc interval greater than 500 milliseconds)
  • Class II or greater New York Heart Association Functional Classification criteria (appendix III) or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)
  • Active autoimmune disease requiring immunosuppressive therapy
  • History of severe asthma, presently on chronic medications (a history of mild asthma requiring inhaled steroids only is eligible)
  • New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan unless cleared for study by Pulmonary. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections).
  • Active uncontrolled bacterial, fungal, or viral infections - all prior infections must have resolved following optimal therapy
  • Known hypersensitivity to any of the study agents used
  • For MM patients only:

    • Prior radiotherapy within 2 weeks prior to the administration of study drug"
    • Surgery within 4 weeks
    • Chemo within 3 weeks (6 weeks for melphalan, or monoclonal antibodies)
  • Received investigational drugs within the 14 days before 1st dose of study drug
  • High titer of donor specific anti-HLA antibodies (MFI >1000)

DONOR INCLUSION CRITERIA:

  • HLA-haploidentical or mismatched related donor/recipient match based on a minimum of intermediate resolution DNA based Class I typing of the A and B locus (at least 2/4 class I allele) and absence of recipient anti HLA antibodies
  • 12 to 70 years of age - Priority should be given to age (<35 years), followed by HLA matching (haploidentical and if not available then fully mismatched donor).
  • At least 40 kilogram body weight
  • In general good health as determined by the evaluating medical provider
  • Adequate organ function defined as:

    • Hematologic: hemoglobin, WBC, platelet within 10% of upper and lower limit of normal range of test (gender based for hemoglobin),
    • Hepatic: ALT < 2 x upper limit of normal,
    • Renal: serum creatinine < 1.8 mg/dl
  • Performance of a donor infectious disease screen panel including CMV Antibody, Hepatitis B Surface Antigen, Hepatitis B Core Antibody, Hepatitis C Antibody, HIV PCR, HIV ½ Antibody, HTLVA ½ Antibody, Rapid Plasma (RPR) Treponema , Trypanosoma Cruzi (T. Cruzi), HCV by NAT, HIV by NAT and WNV (West Nile Virus) by NAT or per current panel - must be negative for HIV and active hepatitis B
  • Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of apheresis
  • Able and willing to undergo apheresis
  • Voluntary written consent (using assent form if donor < 18 years of age)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Timothy Krepski, RN 612-273-2800 tkrepsk1@fairview.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03019666
Other Study ID Numbers  ICMJE 2015LS057
MT2015-46 ( Other Identifier: Masonic Cancer Center, University of Minnesota )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Masonic Cancer Center, University of Minnesota
Study Sponsor  ICMJE Masonic Cancer Center, University of Minnesota
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Veronika Bachanova, MD, PhD University of Minnesota
PRS Account Masonic Cancer Center, University of Minnesota
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP